Stay updated with breaking news from Jay Lichter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Avalon BioVentures unveiled new portfolio company Arialys Therapeutics. The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder.
FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential... | May 8, 2023
Founded in 2008, Otonomy worked on a variety of treatments for ear diseases but suffered setbacks in recent clinical trials
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!